

To: [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted]
From: [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted]
Sent: Wed 3/3/2021 5:27:47 PM
Subject: Re: FW: VE after one dose
Received: Wed 3/3/2021 5:27:48 PM

Thanks [redacted]

[redacted] do you know why there is not so much extra available for Pfizer? About [redacted]. What is the reason for that?

This is relevant for the discussion Tomorrow.

Regards [redacted]

Van: [redacted] <[redacted]@rivm.nl>
Datum: 3 maart 2021 om 09:52:51 CET
Aan: [redacted] <[redacted]@rivm.nl>, [redacted] <[redacted]@rivm.nl>, [redacted]
 <[redacted]@rivm.nl>, [redacted] <[redacted]@rivm.nl>
Onderwerp: Re: FW: VE after one dose

Hi [redacted]

Sorry for the delay, here is a table of the number of doses given by vaccine type and scenario. **All of the results are the total number of vaccines allocated up to 1 July 2021.** I wasn't sure what time frame was most useful, so picked a relatively short term time frame. I can change it if necessary, so please let me know!

I've also included a couple of plots: the first (vac_allocation_totals.jpg) is a plot of the total number of doses (separated by first and second dose) for the 3 different scenarios under consideration by vaccine. The second plot (vac_allocation_by_age_group.jpg) is further broken up by age group.

For both plots:

A = original strategy

B = delay 3 months

C = no 2nd doses

As you can see, based on the distribution schedules there is not a massive difference in the number of first doses of pfizer given between the 3 scenarios, which may explain why the difference in the modelling results was so minimal. I have to assume this is due to availability, but the people who create the distribution schedule would know more.

Please let me know if you have any questions.

Best,

[redacted]

From: 5.1.2e
Sent: Tuesday, 2 March 2021 10:55:19
To: 5.1.2e; 5.1.2e; 5.1.2e; 5.1.2e
Subject: RE: FW: VE after one dose

Hi 5.1.2e

Thanks – the document will have gone to the GR by then – it is not a problem if this is not included – I think it is useful as background info for 5.1.2e (who will attend the GR meeting Thursday evening I believe) – so if it is no too much work it would be useful as a ballpark figure by then.

With best wishes,

5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: dinsdag 2 maart 2021 10:50
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>
Subject: Re: FW: VE after one dose

Hi 5.1.2e

It's not a standard output from the model, but I can calculate it. However, I won't be able to look into it until later this afternoon. Will that be ok?

Best,

5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: Monday, 1 March 2021 22:58
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>
Subject: Re: FW: VE after one dose

Hi 5.1.2e,

One more question that came up today: how many people can be vaccinated how much earlier if we postpone 2nd pfizer dose to 3 months? Is this figure available from your model?

5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Date: 26 February 2021 at 17:51:45 CET
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>
Subject: Re: FW: VE after one dose


Hi 5.1.2e

That's fine. I'd be interested to hear any feedback.

Fijn weekend!

Groeten,

5.1.2e



5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2i

5.1.2e

5.1.2e

From: 5.1.2e

Sent: Friday, 26 February 2021 15:38:58

To: 5.1.2e ; 5.1.2e ; 5.1.2e

Subject: VE after one dose

Hi 5.1.2e


In your sensitivity analyses we assumed a VE of 51% for Pfizer after the first dose – based on waning we thought to see in the Scottish data. 5.1.2e seems to say this is not much of an issue – as per below. This is the OR, $VE=1-OR$.

Maybe the assumption of 51% is too low – what would be a better value for the sensitivity analyses?

5.1.2e

From: 5.1.2e <5.1.2e@phe.gov.uk>
Sent: vrijdag 26 februari 2021 15:03
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@phe.gov.uk>
Subject: RE: First impact figures Netherlands

No the Scottish data is a bit random - we did not show this with the SIREN data, or our TNCC data, or our data on hospitalisation (below)



From: 5.1.2e <5.1.2e@rivm.nl>

Sent: 26 February 2021 10:59

To: [redacted] <[redacted]@phe.gov.uk>; [redacted] <[redacted]@phe.gov.uk>

Subject: First impact figures Netherlands

Dear [redacted]

Just to let you know that we've published our first impact figures:

<https://www.rivm.nl/nieuws/eerste-effecten-vaccinatie-zichtbaar-onder-bewoners-verpleeghuizen>

There is clear impact on the incidence of notified cases in residents of care homes ('verpleeghuizen'), not so much in other elderly where the coverage is still low.

Thanks for publishing your PHE estimates (file 22 feb), this is very helpful.

We're at the moment discussing changes in the programme: giving AZ also to people over 65; giving already infected people only one dose; and deferral of the 2nd dose to 3 months for Pfizer. For the latter we were a bit concerned to see some waning after one Pfizer dose in the Scottish results (Vasileiou et al). Do you think this is real?

With best wishes,

[redacted]

[redacted]

[redacted]

[redacted]

Department for the National Immunisation Programme (RVP)

Centre for Epidemiology and Surveillance of Infectious Diseases (EPI)

National Institute for Public Health and the Environment (RIVM)

[redacted] [@rivm.nl](mailto:[redacted]@rivm.nl)

Tel + [redacted]

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

***** The information contained in the Email and any attachments is confidential and intended solely and for the attention and use of the named addressee(s). It may not be disclosed to any other person without the express authority of the PHE, or the intended recipient or both. If you are not the intended recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also confirms that this Email has been swept for computer viruses by Exchange Online Protection, but please re-sweep any attachments before opening or saving. [HTTP://www.phe.gov.uk](http://www.phe.gov.uk) *****